R&D From in silico to in vivo: Why development strategy now dete... As discovery becomes faster and more accessible, the differentiator shifts downstream.
R&D Changing Faces: Pharma and biotech, March 2026 A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.
R&D Sponsored A data-driven guide to small molecule drug discovery and dev... A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
R&D Looking to gene therapy for ocular diseases, with Lance Bald... Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.
R&D Redefining drug discovery: Morocco’s biotech strategy for in... Ongoing work in Morocco demonstrates how developing research infrastructure can support innovative approaches grounded in locally generated data.
R&D LSX2026: On a therapeutic vision for ocular disease, with Al... Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
